Axsome Therapeutics (AXSM) Tops Q4 EPS by 17c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($0.56), $0.17 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $195.99 million versus the consensus estimate of $189.81 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Increasing unusual put volume: MNDY BILI HWM SHW NVS AEP GRAB AXTX STT CAMT XEL TRIP ROST BCRX SBLK
• Citi reiterates Buy rating on AMD with $575 price target post TMT conference